- Home
- AUST vs JAGX Comparison
AUST vs JAGX Comparison
Compare AUST & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- JAGX
- Stock Information
- Founded
- AUST 2020
- JAGX 2013
- Country
- AUST Canada
- JAGX United States
- Employees
- AUST N/A
- JAGX N/A
- Industry
- AUST
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- JAGX Health Care
- Exchange
- AUST Nasdaq
- JAGX Nasdaq
- Market Cap
- AUST 15.5M
- JAGX 12.9M
- IPO Year
- AUST 2022
- JAGX N/A
- Fundamental
- Price
- AUST $1.25
- JAGX $0.83
- Analyst Decision
- AUST
- JAGX
- Analyst Count
- AUST 0
- JAGX 0
- Target Price
- AUST N/A
- JAGX N/A
- AVG Volume (30 Days)
- AUST 92.5K
- JAGX 524.3K
- Earning Date
- AUST 03-03-2025
- JAGX 11-13-2024
- Dividend Yield
- AUST N/A
- JAGX N/A
- EPS Growth
- AUST N/A
- JAGX N/A
- EPS
- AUST N/A
- JAGX N/A
- Revenue
- AUST N/A
- JAGX $10,480,000.00
- Revenue This Year
- AUST N/A
- JAGX $18.18
- Revenue Next Year
- AUST N/A
- JAGX $40.06
- P/E Ratio
- AUST N/A
- JAGX N/A
- Revenue Growth
- AUST N/A
- JAGX N/A
- 52 Week Low
- AUST $0.62
- JAGX $0.81
- 52 Week High
- AUST $3.19
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- AUST 46.23
- JAGX 38.30
- Support Level
- AUST $1.05
- JAGX $0.84
- Resistance Level
- AUST $1.27
- JAGX $0.90
- Average True Range (ATR)
- AUST 0.10
- JAGX 0.10
- MACD
- AUST 0.03
- JAGX -0.03
- Stochastic Oscillator
- AUST 64.82
- JAGX 3.58
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.